 "Siegfried's Nantong facility in China")
Swiss life sciences company Siegfried Group has received the final operating approval from the Chinese Environmental Protection Bureau (EPB) for its Nantong production site. Consequently, all approvals and certificates required by the authorities for large-scale production have now been obtained. Trial operation for the commercial facilities already started a year ago.
The production capacity of Siegfried’s Nantong site, located in China’s industrial park northwest of Shanghai, amounts to 350 cubic meters. This significant site addition to Siegfried’s production network in a cost-effective production environment strengthens the company’s long-term competitiveness. The facility was inaugurated in August 2015 and is attracting a great deal of interest from customers.
Dr Walter Kittl, head global operations of Siegfried, “Thanks to the final operation approval of the Chinese Environmental Protection Bureau our production network and thus our customers can now profit from a modern multi-purpose plant, complying with highest safety, environmental and quality standards.”
The pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.
Siegfried, active in both the primary and secondary production of drugs, develops and manufactures active pharmaceutical ingredients (APIs) for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
